CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
pneumococcal polyvalent vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00445484
NCT00445484Phase 2Completed
CompareCT.gov

Revlimid to Augment Efficacy of Prevnar Vaccines in Patients With Relapsed or Refractory Myeloma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Mar 9, 2007·Updated Aug 24, 2015

In Brief

A Phase 2 clinical trial evaluating pneumococcal polyvalent vaccine and lenalidomide for Multiple Myeloma and Plasma Cell Neoplasm. Completed, enrolled 22 participants across 1 site.

Detailed Summary

RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Vaccines may help the body build an effective immune response to kill cancer cells. Giving lenalidomide together with vaccine therapy may make a stronger immune response and kill more cancer cells. PURPOSE: This phase II trial is studying how well giving lenalidomide together with vaccine therapy works in treating patients with relapsed or refractory multiple myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma and Plasma Cell Neoplasm
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 9, 2007
Enrollment StartJan 1, 2007
Primary CompletionApr 1, 2009
Study CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 19.3 years ago

Interventions

pneumococcal polyvalent vaccinebiological

Given intramuscularly

lenalidomidedrug

Given orally